PUMA BIOTECHNOLOGY, INC. Expense Breakdown
No Expense Breakdown for PBYI on this site yet.
- 2026-06-30: Development and Commercialization of Innovative Products to Enhance Cancer Care $12.47M.
- 2025-06-30: Development and Commercialization of Innovative Products to Enhance Cancer Care $12.30M.
Source checked: the stored Expense Breakdown page for PBYI.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Development and Commercialization of Innovative Products to Enhance Cancer Care |
|---|
| 2026-06-30 | $12.47M |
|---|
| 2025-06-30 | $12.30M |
|---|
Costs and Expenses: each quarter (3 month)
| Quarter end | Development and Commercialization of Innovative Products to Enhance Cancer Care |
|---|
| 2026-06-30 | $48.92M |
|---|
| 2025-06-30 | $45.80M |
|---|
General and Administrative Expense: each quarter (3 month)
| Quarter end | Development and Commercialization of Innovative Products to Enhance Cancer Care |
|---|
| 2026-06-30 | $5.09M |
|---|
| 2025-06-30 | $6.54M |
|---|
Operating expenses: each quarter (3 month)
| Quarter end | Development and Commercialization of Innovative Products to Enhance Cancer Care |
|---|
| 2026-06-30 | $46.96M |
|---|
| 2025-06-30 | $44.17M |
|---|
Selling And Marketing Expense: each quarter (3 month)
| Quarter end | Development and Commercialization of Innovative Products to Enhance Cancer Care |
|---|
| 2026-06-30 | $11.28M |
|---|
| 2025-06-30 | $10.52M |
|---|